Merus Announces Chief Executive Officer Transition

Merus announced Dr. Ton Logtenberg will step down as CEO, President, Principal Financial Officer and Director of the Company on December 31, 2019. The Merus Board of Directors has nominated Dr. Sven (Bill) Ante Lundberg, currently a non-executive director on the Merus board, to succeed Dr. Logtenberg as CEO, President and Principal Financial Officer of Merus. In accordance with Dutch law, the appointment will be voted on during an extraordinary general meeting of shareholders on December 31, 2019. Dr. Logtenberg will remain on as a senior advisor for Merus during the transition over the next year.

"As founder, CEO and President of Merus, it has been a great privilege to lead the Company for the past 16 years," said Dr. Ton Logtenberg. "Together, we transformed a vision for a best-in-class bispecific antibody technology into a global, clinical-stage biotechnology company. I am incredibly proud of the team and our accomplishments, and I am also exceedingly optimistic about what the future holds for Merus. It has been an honor to serve Merus in its mission to deliver innovative therapeutics to patients with life-threatening diseases, and I am delighted to have Bill take the helm as CEO and President, and continue to further our shared vision and goals."

Dr. Bill Lundberg joined Merus’ Board of Directors in June 2019, and he brings more than 15 years of experience managing and leading biotechnology research and development along with a background as a medical oncologist. He has experience across all aspects and phases of drug development in both academic and industry settings. Most recently, Dr. Lundberg served as Chief Scientific Officer at CRISPR Therapeutics and as Head of Translational Medicine at Alexion Pharmaceuticals.

"On behalf of the entire Company and the Board of Directors, I would like to extend our sincerest appreciation to Ton for his unwavering inspirational leadership and dedication," Dr. Russell Greig, Chairman of the Board of Directors, said. "Under his direction, Merus has transformed from what began with a vision of developing novel antibody therapeutics into a leading multispecific antibody company with four promising candidates in clinical development today. Ton’s strong belief in science and technology as the basis for the discovery of innovative medicines has provided the company with a unique platform for a steady pipeline of differentiated drug candidates for patients with unmet medical needs.

"I’m grateful for the opportunity to lead Merus during this exciting time for the organization," said Dr. Lundberg. "I look forward to working closely with Ton and the Merus team to build on the momentum of the Company’s successes, including recent clinical proof of concept data for zenocutuzumab (MCLA-128) in patients with solid tumors harboring NRG1 fusions, advancing our current programs through the clinic and accelerating our leading multispecific antibody platforms to further expand a pipeline of highly innovative medicines to patients in need."

Dr. Bill Lundberg most recently served as Chief Scientific Officer at CRISPR Therapeutics, establishing the company in Cambridge, Mass., and leading the development of the company’s first clinical trial application. Previously, he served as Head of Translational Medicine at Alexion Pharmaceuticals and Chief Medical Officer of Taligen Therapeutics. He also held roles of increasing responsibility in clinical drug development and medical affairs at Xanthus/Anthsoma, Wyeth and Genzyme. Dr. Lundberg received an MD from Stanford University, an MBA from the University of Massachusetts and a BS from Massachusetts Institute of Technology. He completed post-doctoral training at the Whitehead Institute/MIT, and clinical training in Medicine and Medical Oncology from Harvard Medical School and the Dana-Farber Cancer Institute.

Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the reproduced articles,

please email: Julia.Zhang@ubmsinoexpo.com to motify or remove the content.